Sionna Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 |
|---|---|---|---|
| Income Statement | |||
| Research and development | $60.3M | $57.3M | — |
| Operating expenses | $89.0M | $70.6M | — |
| Operating income | -$89.0M | -$70.6M | — |
| Income tax expense | $0 | $0 | — |
| Net income | -$75.3M | -$61.7M | — |
| Balance Sheet | |||
| Cash and equivalents | $58.5M | $37.8M | — |
| Current assets | $241.4M | $151.0M | — |
| Total assets | $326.0M | $185.8M | — |
| Current liabilities | $11.7M | $10.4M | — |
| Total liabilities | $19.1M | $19.1M | — |
| Stockholders' equity | $306.8M | -$163.7M | -$114.9M |
| Cash Flow Statement | |||
| Cash from operations | -$66.3M | -$52.8M | — |
| Depreciation and amortization | $647,000 | $668,000 | — |
| Stock-based compensation | $12.1M | $3.7M | — |
| Capital expenditure | $377,000 | $27,000 | — |
| Free cash flow | -$66.7M | -$52.8M | — |
Shares outstanding 45.2M · Free float 71.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.